Article ID Journal Published Year Pages File Type
8518754 Phytomedicine 2017 16 Pages PDF
Abstract
The combination of natural products (e.g. the sesquiterpenoid artesunate) and synthetic compounds (e.g. the small molecule EGFR tyrosine kinase inhibitor erlotinib) may lead to improved clinical success rates in oncology.
Keywords
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Clinical Biochemistry
Preview
Cancer combination therapy of the sesquiterpenoid artesunate and the selective EGFR-tyrosine kinase inhibitor erlotinib
Authors
,